Key points are not available for this paper at this time.
Kidney diseases pose a significant threat to global public health, with early diagnosis and accurate monitoring being crucial for improving patient outcomes. However, traditional kidney disease markers such as serum creatinine and blood urea nitrogen have limitations in sensitivity and specificity. In recent years, rapid advancements in molecular biology and proteomics have led to the discovery of a series of novel biomarkers that are gradually being applied in clinical practice. This review examines novel kidney disease biomarkers, including cystatin C (Cys-C), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1). These markers not only reflect kidney injury earlier and more accurately but may also provide important bases for kidney disease classification, severity assessment, and prognosis prediction. Additionally, this paper explores the potential of multi-marker combined detection strategies in improving diagnostic accuracy. Although these novel markers show immense potential, they still face challenges such as standardization and cost-effectiveness before widespread clinical application. Future research should focus on optimizing detection methods, establishing clinical decision thresholds, and evaluating the value of these markers in personalized medicine, thereby paving new paths for precise diagnosis and treatment of kidney diseases.
Pu et al. (Sat,) studied this question.